Use of peroxiredoxin for preconditioning of heterotopic heart transplantation in a rat

Peroxiredoxin 6 (Prdx6) is an antioxidant enzyme in the human body that performs a number of important functions in the cell. Prdx6 restores a wide range of peroxide substrates, thus playing a leading role in maintaining redox homeostasis in mammalian cells. In addition to peroxidase activity, Prdx6 has an activity of phospholipase A2, thus taking part in membrane phospholipid metabolism. Due to its peroxidase and phospholipase activity, Prdx6 participates in intracellular and intercellular signal transmission, thereby facilitating the initiation of regenerative processes in the cell, suppression of apoptosis and activation of cell proliferation. Given the functions performed, Prdx6 can effectively deal with oxidative stress caused by various factors, including ischemia-reperfusion injury. On an animal model of rat heterotopic heart transplantation, we showed the cardioprotective potential of exogenous recombinant Prdx6, introduced before transplantation and subsequent reperfusion injury of the heart. It has been demonstrated that exogenous Prdx6 effectively alleviates the severity of ischemia-reperfusion injury of the heart by 2–3 times, providing normalization of its structural and functional state during heterotopic transplantation. The use of recombinant Prdx6 can be an effective approach in preventing/alleviating ischemia-reperfusion injury of the heart, as well as in maintaining an isolated heart during transplantation.

ischemia-reperfusion injury, peroxiredoxin, heterotopic heart transplantation

1. Alam SR, Lewis SC, Zamvar V, Pessotto R, Dweck MR, Krishan A et al. Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial. Heart. 2015; 101 (20): 1639–1645. doi: 10.1136/heartjnl-2015-307745.

2. Conroy F, Yewdall NA. Peroxiredoxin Proteins as Building Blocks for Nanotechnology. Methods Mol Biol. 2020; 2073: 39–54. doi: 10.1007/978-1-4939-9869-2_3.

3. Fisher AB. The phospholipase A2 activity of peroxiredoxin 6. J Lipid Res. 2018; 59 (7): 1132–1147. doi: 10.1194/jlr.R082578.

4. Novoselov VI, Ravin VK, Sharapov MG. Modified peroxiredoxins as prototypes of drugs with powerful antioxidant action. BIOPHYSICS. 2011; 56: 836–842. [In Russ].

5. Rhee SG. Overview on Peroxiredoxin. Mol Cells. 2016 Jan; 39 (1): 1–5.

6. Sharapov MG, Novoselov VI, Fesenko EE, Bruskov VI, Gudkov SV. The role of peroxiredoxin 6 in neutralization of X-ray mediated oxidative stress: effects on gene expression, preservation of radiosensitive tissues and postradiation survival of animals. Free Radic Res. 2017; 51 (2): 148–166. doi: 10.1080/10715762.2017.1289377.

7. Sharapov MG, Novoselov VI, Gudkov SV. Radioprotective Role of Peroxiredoxin 6. Antioxidants (Basel). 2019; 8 (1) doi: 10.3390/antiox8010015.

8. Sharapov MG, Novoselov VI, Ravin VK. Construction of a Fusion Enzyme Exhibiting Superoxide Dismutase and Peroxidase Activity. Biochemistry (Mosc). 2016; 81 (4): 420–427.

9. Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A et al. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem. 2003; 4 (278, 27): 25179– 25190.

10. Bunenkov NS, Bunenkova GF, Komok VV, Grinenko OA, Nemkov AS. SAS Enterprise Guide 6.1 for physicians: multiple comparisons. Medical academic journal. 2019; 19 (4): 33–40. doi: 10.17816/ MAJ17736. [In Russ.].

11. Bunenkov NS, Bunenkova GF, Beliy SA, Komok VV, Grinenko OA, Nem kov AS. SAS Enterprise Guide 6.1 for physicians: getting started. Medical academic journal. 2019; 19 (3): 27–36. doi: 10.17816/MAJ19327-36. [In Russ.].

12. Galagudza MM, Sonin DL, Pochkaeva EI. The no-reflow phenomenon: mechanisms and therapeutic targets. Regional blood circulation and microcirculation. 2018; 17 (1): 5–12. doi: 10.24884/1682-6655-2018-17-1-5-12. [In Russ.].

13. Galagudza MM, Minasian SM, Dmitriev YuV, Poleschenko YaI, Shubina PYu, Protsak ES et al. Comparison of hemodynamic and infarct-limiting effects of preservation solution based on Krebs–Henseleit buffer and HTK solution in the rat model of heterotopic heart transplantation. «Arterial’naya Gipertenziya» («Arterial Hypertension»). 2019; 25 (1): 84–89. [In Russ.] doi: 10.18705/1607-419X-2019-25-1-84-89.

14. Gautier SV. 1000 heart transplantations in one center. Russian Journal of Transplantology and Artificial Organs. 2018; 20 (2): 5. [In Russ].

15. Minasian SM, Galagudza MM, Dmitriev YuV, Karpov AA, Bobrova EA, Krasichkov AS et al. Donor heart preservation: history and current status in terms of translational medicine. Regional blood circulation and microcirculation. 2014; 13 (3): 4–16. [In Russ.]. doi: 10.24884/1682-6655-2014-13-3-4-16.

16. Molchan NS, Polushin YuS, Zhloba AA, Kobak AE, Khryapa SS. Is it possible to augment myocardial protection during cardiopulmonary bypass by administration of inhalational anesthetics? Almanac of Clinical Medicine. 2019; 47 (3): 221–227. [In Russ.]. doi: 10.18786/2072-0505- 2019-47-036.

17. Sokolov AV, Kostevich VA, Gorbunov NV, Grigorieva DV, Gorudko IV, Vasilyev VB et al. A link between active myeloperoxidase and chlorinated ceruloplasmin in blood plasma of patients with cardiovascular diseases. Medical Immunology (Russia). 2018; 20 (5): 699–710. [In Russ.]. doi: 10.15789/1563-0625-2018-5-699-710.

18. Khubulava GG, Shishkevich AN, Mihajlov SS, Bessonov EYu. Sindrom reperfuzii miokarda: patogenez, klinika, diagnostika. Vestnik Rossijskoj voenno-medicinskoj akademii. 2020; 1 (69): 196–200. [In Russ.].

19. Sharapov MG, Novoselov VI, Ravin VK. Klonirovanie, ekspressiya kDNK i sravnitel’nyj analiz peroksiredoksina 6 razlichnyh organizmov. Molekulyarnaya biologiya. 2009; 43 (3): 505–511. [In Russ.].